CO6270206A2 - Producto de dispersion solida de drogas basadas en n-aril urea - Google Patents
Producto de dispersion solida de drogas basadas en n-aril ureaInfo
- Publication number
- CO6270206A2 CO6270206A2 CO10049271A CO10049271A CO6270206A2 CO 6270206 A2 CO6270206 A2 CO 6270206A2 CO 10049271 A CO10049271 A CO 10049271A CO 10049271 A CO10049271 A CO 10049271A CO 6270206 A2 CO6270206 A2 CO 6270206A2
- Authority
- CO
- Colombia
- Prior art keywords
- solid dispersion
- dispersion product
- pharmaceutically acceptable
- agent
- matrix forming
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un producto de dispersion solida que comprende al menos un agente con actividad farmacéutica, que se obtiene a) preparando una mezcla liquida que contiene el al menos un agente activo, al menos un agente formador de matriz farmacéuticamente aceptable, al menos un agente tensioactivo farmacéuticamente aceptable y al menos un solvente, y b) eliminando el o los solventes de la mezcla liquida para obtener el producto de dispersion solida.2.- El producto de dispersion solida de la reivindicacion 1, donde se agrega al menos un relleno a la mezcla liquida antes de eliminar el o los solventes. 3.- El producto de dispersion solida de la reivindicacion 1, donde la relacion de masa entre el agente activo y el agente formador de matriz farmacéuticamente aceptable es de entre 0,01:1 y 1:3. 4.- El producto de dispersion solida de la reivindicacion 1, donde la relacion de masa entre el agente activo y el agente tensioactivo farmacéuticamente aceptable es de entre 0,1:1 y 1:7. 5.- El producto de dispersion solida de la reivindicacion 1, donde el agente formador de matriz farmacéuticarnente aceptable se selecciona del grupo que consiste en ciclodextrinas, polimeros farmacéuticamente aceptables, lipidos o combinaciones de dos o mas de los anteriores. 6.- El producto de dispersion solida de la reivindicacion 1, donde dicho agente formador de matriz farmacéuticamente aceptable se selecciona del grupo que consiste en ésteres de celulosa, éteres de celulosa, rnaltodextrinas, homopolimeros de N-vinil pirrolidona, copolimeros de N-vinil pirrolidona y combinaciones de dos o mas de los anteriores. 7.- El producto de dispersion solida de la reivindicacion 1, donde dicho agente formador de matriz farmacéuticamente aceptable se selecciona del grupo que consiste en poli N-vinilpirrolidonas, copolimeros de N-vinil pirrolidona y acetato de vinilo y combinaciones de los anteriores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99961807P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270206A2 true CO6270206A2 (es) | 2011-04-20 |
Family
ID=40089463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10049271A CO6270206A2 (es) | 2007-10-19 | 2010-04-27 | Producto de dispersion solida de drogas basadas en n-aril urea |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2197425A2 (es) |
| JP (1) | JP2011500649A (es) |
| KR (1) | KR20100087170A (es) |
| CN (1) | CN101827584A (es) |
| AU (1) | AU2008313622A1 (es) |
| BR (1) | BRPI0818340A2 (es) |
| CA (1) | CA2699301A1 (es) |
| CO (1) | CO6270206A2 (es) |
| CR (1) | CR11442A (es) |
| DO (1) | DOP2010000117A (es) |
| EC (1) | ECSP10010183A (es) |
| GT (1) | GT201000102A (es) |
| MX (1) | MX2010004291A (es) |
| PA (1) | PA8800101A1 (es) |
| RU (1) | RU2010119929A (es) |
| UA (1) | UA100865C2 (es) |
| WO (1) | WO2009050291A2 (es) |
| ZA (1) | ZA201002095B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| KR20130109092A (ko) * | 2010-06-09 | 2013-10-07 | 아보트 러보러터리즈 | 키나제 억제제를 함유하는 고체 분산물 |
| WO2013070996A1 (en) | 2011-11-11 | 2013-05-16 | Novartis Ag | Method of treating a proliferative disease |
| KR102091295B1 (ko) | 2011-11-23 | 2020-03-19 | 어레이 바이오파마 인크. | 제약 제제 |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| WO2014003677A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising solid dispersion particles containing tadalafil |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009513642A (ja) * | 2005-10-25 | 2009-04-02 | アボット・ラボラトリーズ | 低水溶解度の薬剤を含む製剤およびそれの使用方法 |
| WO2007066189A2 (en) * | 2005-12-09 | 2007-06-14 | Pfizer Products Inc. | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
| WO2008055966A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2008
- 2008-10-17 UA UAA201006029A patent/UA100865C2/ru unknown
- 2008-10-17 WO PCT/EP2008/064076 patent/WO2009050291A2/en active Application Filing
- 2008-10-17 JP JP2010529408A patent/JP2011500649A/ja active Pending
- 2008-10-17 CA CA2699301A patent/CA2699301A1/en not_active Abandoned
- 2008-10-17 MX MX2010004291A patent/MX2010004291A/es not_active Application Discontinuation
- 2008-10-17 BR BRPI0818340 patent/BRPI0818340A2/pt not_active IP Right Cessation
- 2008-10-17 KR KR1020107010979A patent/KR20100087170A/ko not_active Application Discontinuation
- 2008-10-17 EP EP08839333A patent/EP2197425A2/en not_active Withdrawn
- 2008-10-17 RU RU2010119929/15A patent/RU2010119929A/ru not_active Application Discontinuation
- 2008-10-17 AU AU2008313622A patent/AU2008313622A1/en not_active Abandoned
- 2008-10-17 PA PA20088800101A patent/PA8800101A1/es unknown
- 2008-10-17 CN CN200880112150A patent/CN101827584A/zh active Pending
-
2010
- 2010-03-24 ZA ZA2010/02095A patent/ZA201002095B/en unknown
- 2010-04-16 GT GT201000102A patent/GT201000102A/es unknown
- 2010-04-16 DO DO2010000117A patent/DOP2010000117A/es unknown
- 2010-04-27 CO CO10049271A patent/CO6270206A2/es not_active Application Discontinuation
- 2010-05-17 EC EC2010010183A patent/ECSP10010183A/es unknown
- 2010-05-19 CR CR11442A patent/CR11442A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009050291A2 (en) | 2009-04-23 |
| KR20100087170A (ko) | 2010-08-03 |
| EP2197425A2 (en) | 2010-06-23 |
| JP2011500649A (ja) | 2011-01-06 |
| CA2699301A1 (en) | 2009-04-23 |
| CR11442A (es) | 2010-09-06 |
| AU2008313622A1 (en) | 2009-04-23 |
| RU2010119929A (ru) | 2011-11-27 |
| MX2010004291A (es) | 2010-08-02 |
| BRPI0818340A2 (pt) | 2015-04-22 |
| PA8800101A1 (es) | 2009-05-15 |
| DOP2010000117A (es) | 2010-05-15 |
| ECSP10010183A (es) | 2010-06-29 |
| GT201000102A (es) | 2012-03-12 |
| CN101827584A (zh) | 2010-09-08 |
| WO2009050291A3 (en) | 2010-04-08 |
| ZA201002095B (en) | 2011-11-30 |
| UA100865C2 (ru) | 2013-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6270206A2 (es) | Producto de dispersion solida de drogas basadas en n-aril urea | |
| DOP2010000114A (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
| Kurakula et al. | Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition | |
| US10632074B2 (en) | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product | |
| AR001458A1 (es) | Composición farmacéutica para la administración transdérmica. | |
| MX2015012433A (es) | Matriz de microestructura para suministro de agentes activos. | |
| PE20071139A1 (es) | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido | |
| AR077411A2 (es) | Forma de dosificacion farmaceutica solida, con lopinavir y ritonavir, y proceso para su preparacion. | |
| RU2004137118A (ru) | Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления | |
| CR9704A (es) | Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma. | |
| WO2010015567A3 (en) | Controlled release formulations using intelligent polymers | |
| ES2183602T3 (es) | Formulaciones microencapsuladas. | |
| AR080736A1 (es) | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla | |
| RU2488384C2 (ru) | Композиции для лечения неопластических заболеваний | |
| AR045193A1 (es) | Composicion de fexofenadina y proceso de preparacion | |
| JP2010536837A5 (es) | ||
| AR061830A1 (es) | Formulacion liquida no acuosa altamente eficaz de piretroides | |
| MX2023003556A (es) | Composiciones farmaceuticas. | |
| UA83036C2 (ru) | Фармацевтическая композиция в виде гидрогеля для трансдермального введения в организм действующих веществ | |
| AR048432A1 (es) | Composiciones diureticas de liberacion prolongada | |
| PE20110923A1 (es) | Formulaciones de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral | |
| AR078167A1 (es) | Dispersion solida que comprende un agente anti-vih | |
| CO6270249A2 (es) | Fibra, pelicula o espuma que comprende un plastificador y un gel ligado a arcilla cargado y metodos para su produccion | |
| Charoensumran | Development of Polystyrene-based Organogels Swollen in D-limonene for Transdermal Drug Delivery | |
| WO2021204634A1 (fr) | Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l'amitriptyline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |